I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Brexucabtagene autoleucel approval marked a significant advancement in MCL treatment, achieving a 62% complete remission rate in resistant or relapsed patients. Prognostic tools like the Ki-67 index ...

Soccer Hall-of-Famer is speaking out for the first time about his private battle with lymphoma and treatment with Breyanzi in ...

Updated FDA labeling for Yescarta now includes patients with relapsed or refractory primary CNS lymphoma, expanding treatment options for this group.

The Global Peripheral T-Cell Lymphoma Market is poised for significant growth, driven by a rising incidence of lymphoma and adoption of novel targeted therapies and immunotherapies. Peripheral T-cell ...

The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Yescarta (axicabtagene ...